Heterogeneity between insulin and proinsulin in the potency for insulin autoantibodies in newly diagnosed type 1 diabetes children
Clinical and Experimental Immunology · 06.01.2026 · 220 (1)
DOI: 10.1093/cei/uxag026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 05.05.2026. Verfasst von Pantea Parsian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Lund University CRC, Skåne University Hospital, Malmö, Sweden. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Proinsulin, Insulin, Insulin Antibodies. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Diabetesfonden, Sydvästra Skånes Diabetesförening.
Themen: Diabetes mellitus, Kinderkrankenpflege
Abstract (Originalsprache)
Autoantibodies against insulin (IAA) are early appearing markers of autoimmunity against the pancreatic islet beta cells and predict progression to type 1 diabetes if additional islet autoantibodies also develop. It is still controversial if proinsulin rather than insulin is the primary autoantibody. The aim of the present study was to compare the half-maximal concentration (IC50) between insulin and proinsulin to displace the binding of insulin to insulin autoantibodies (IAA) in the Antibody Detection by Agglutination PCR (ADAP) assay. IC50 as a measure of potency to displace insulin binding to IAA was determined in 36 newly diagnosed type 1 diabetes children. The ability of either insulin or proinsulin to displace IAA was heterogenous. Proinsulin curves were consistently right-shifted relative to insulin as median IC50 was 21.0 nM (IQR 14.9–25.1) for insulin and 26.1 nM (IQR 12.3–37.5) for proinsulin. A significant age × sex interaction was observed (F (1,31) = 14.3, P < 0.001), indicating that IC50 for both insulin and proinsulin increased with age in boys but decreased in girls. It may reflect whether autoantibodies to insulin or proinsulin were first appearing or of variable maturation from the time of initiation through progression to clinical onset. It was concluded that the IC50 of insulin and proinsulin for IAA was comparable in children with newly diagnosed type 1 diabetes. The ADAP IAA assay should prove useful to determine whether insulin or proinsulin is the primary target at the time of seroconversion to IAA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, Lund University CRC, Skåne University Hospital, Malmö, Sweden.
- The Research and Development Laboratory, Enable Biosciences, Inc., South SanFrancisco, CA, USA.
ORCID-Profile: Pantea Parsian, Åke Lernmark, Josefine Jönsson
Förderung
- Swedish Research Council
- Diabetesfonden
- Sydvästra Skånes Diabetesförening
- The Strategic Research Area Exodiab
- Swedish Foundation for Strategic Research
Zitieren
APA
Parsian, P., Bennet, R., Tsai, C. T., Ramelius, A., Lernmark, Å., Jönsson, J., & BDD Study Group (2026). Heterogeneity between insulin and proinsulin in the potency for insulin autoantibodies in newly diagnosed type 1 diabetes children. Clinical and Experimental Immunology, 220(1). https://doi.org/10.1093/cei/uxag026
Vancouver
Parsian P, Bennet R, Tsai CT, Ramelius A, Lernmark Å, Jönsson J, et al. Heterogeneity between insulin and proinsulin in the potency for insulin autoantibodies in newly diagnosed type 1 diabetes children. Clinical and Experimental Immunology. 2026;220(1). doi:10.1093/cei/uxag026
BibTeX
@article{Parsian2026,
author = {Parsian, Pantea and Bennet, Rasmus and Tsai, Cheng-Ting and Ramelius, Anita and Lernmark, Åke and Jönsson, Josefine and BDD Study Group, BDD Study Group},
title = {Heterogeneity between insulin and proinsulin in the potency for insulin autoantibodies in newly diagnosed type 1 diabetes children},
journal = {Clinical and Experimental Immunology},
year = {2026},
volume = {220},
number = {1},
doi = {10.1093/cei/uxag026}
}
EUVIMED